PMID- 10069662
OWN - NLM
STAT- MEDLINE
DCOM- 19990329
LR  - 20190905
IS  - 0804-4643 (Print)
IS  - 0804-4643 (Linking)
VI  - 140
IP  - 2
DP  - 1999 Feb
TI  - Serum IGF-binding protein-6 and prostate specific antigen in breast cancer.
PG  - 164-8
AB  - OBJECTIVE: Recent studies have demonstrated the presence of the IGF-binding 
      proteins (IGFBPs) and prostate specific antigen (PSA), an IGFBP protease. in 
      human breast tissue. We sought to investigate the differences in serum IGFs, 
      IGFBP-1, -3 and -6, and PSA between patients with surgically proven breast cancer 
      and patients with benign breast disease. DESIGN AND METHODS: Concentrations of 
      IGFs, IGFBP-1, -3 and -6, and PSA were determined in the sera from 57 patients 
      with breast cancer (CA), and 46 women with benign breast disease (BBD) using 
      immunoassays for IGFs and IGFBPs and an ultrasensitive ELISA for PSA. RESULTS: 
      The mean (+/- S.E.M.) serum IGFBP-6 level in the CA group, 127 (16) ng/ml, was 
      statistically significantly lower than in the BBD group, 157 (10) ng/ml (P = 
      0.016). Patients with CA had an elevated geometric mean serum PSA level of 0.018 
      (range: 0.0015-0.107) ng/ml, compared with 0.007 (range: 0.0015-0.019) ng/ml in 
      women with BBD (P = 0.025). Mean serum IGFBP-1 concentrations were significantly 
      lower in the CA group, 16 (2) ng/ml, versus 37 (4) ng/ml in the BBD group (P = 
      0.001). Mean serum IGFBP-3 concentrations were also lower in the CA group versus 
      the BBD group, at 1981 (65) ng/ml, versus 2603 (140) ng/ml (P = 0.002) 
      respectively. In the CA group, statistically significant correlations between PSA 
      and IGFBP-6 (r = 0.413; P = 0.001), and between PSA and IGFBP-1 (r = -0.329; P = 
      0.021) were seen. Differences in IGF-I and -II between the two groups were not 
      statistically significant. CONCLUSION: Lower serum concentrations of IGFBP-6, -3 
      and -1, but higher PSA concentrations were seen in the breast cancer group, and 
      collectively these would suggest that there is an increase in bioavailable IGF-I 
      in breast cancer.
FAU - Kaulsay, K K
AU  - Kaulsay KK
AD  - Department of Medicine, National University of Singapore, Singapore.
FAU - Ng, E H
AU  - Ng EH
FAU - Ji, C Y
AU  - Ji CY
FAU - Ho, G H
AU  - Ho GH
FAU - Aw, T C
AU  - Aw TC
FAU - Lee, K O
AU  - Lee KO
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Endocrinol
JT  - European journal of endocrinology
JID - 9423848
RN  - 0 (Insulin-Like Growth Factor Binding Protein 1)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 3)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 6)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - 67763-97-7 (Insulin-Like Growth Factor II)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Breast Neoplasms/*blood
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Immunoassay
MH  - Insulin-Like Growth Factor Binding Protein 1/blood
MH  - Insulin-Like Growth Factor Binding Protein 3/blood
MH  - Insulin-Like Growth Factor Binding Protein 6/*blood
MH  - Insulin-Like Growth Factor I/analysis
MH  - Insulin-Like Growth Factor II/analysis
MH  - Osmolar Concentration
MH  - Prostate-Specific Antigen/*blood
EDAT- 1999/03/09 00:00
MHDA- 1999/03/09 00:01
CRDT- 1999/03/09 00:00
PHST- 1999/03/09 00:00 [pubmed]
PHST- 1999/03/09 00:01 [medline]
PHST- 1999/03/09 00:00 [entrez]
AID - 10.1530/eje.0.1400164 [doi]
PST - ppublish
SO  - Eur J Endocrinol. 1999 Feb;140(2):164-8. doi: 10.1530/eje.0.1400164.